ENSG — The Ensign Group, Inc.

Summary of Ensign Group, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• GAAP Diluted EPS: $1.67, up 21.9% year-over-year.
• Adjusted Diluted EPS: $1.85, up 21.7%.
• Total Revenue: $1.4 billion, an increase of 18.4%.
• GAAP Net Income: $99.7 million, up 24.2%.
• Adjusted Net Income: $110.2 million, up 23.9%.
• Cash and Cash Equivalents: $539.5 million.
• Cash Flow from Operations: $100.2 million.
• Lease Adjusted Net Debt-to-EBITDA Ratio: 1.73x.
• Quarterly Cash Dividend: $0.065 per share, marking 23 consecutive years of dividend increases.

2. Strategic Updates and Business Highlights:

• Occupancy Rates: Same-store occupancy reached a record high of 84.3%, with transitioning occupancy at 85.1%.
• Skilled Revenue Growth: Same-store skilled revenue increased by 9.6% year-over-year.
• Acquisitions: Added 22 new operations, including 21 real estate assets, bringing total acquisitions since 2024 to 99.
• Clinical Performance: Achieved significant improvements in clinical outcomes, with 85% of operations rated 4- or 5-star by CMS.
• Leadership Stability: Notable decrease in turnover among directors of nursing, down 32% over two years.
• Standard Bearer Healthcare REIT: Generated $36.1 million in rental revenue, with an EBITDAR to rent coverage ratio of 2.7x.

3. Forward Guidance and Outlook:

• Earnings Guidance: Increased to $7.48 to $7.62 per diluted share for 2026, up from $7.41 to $7.61.
• Revenue Guidance: Raised to $5.81 billion to $5.86 billion, up from $5.77 billion to $5.84 billion.
• Confidence in Growth: Management expressed strong confidence in continued operational execution and demographic tailwinds supporting future growth.

4. Bad News, Challenges, or Points of Concern:

• Managed Care Volatility: Although current trends show strong demand, there are concerns regarding potential increased scrutiny from managed care organizations and clinical reviews, which could impact admissions.
• Seasonality Effects: Anticipated seasonal declines in skilled mix and occupancy during Q2 and Q3, which may affect revenue.
• M&A Contributions: Questions arose regarding the impact of recent acquisitions on earnings growth, with some concern that organic growth might be softening.

5. Notable Q&A Insights:

• Clinical Review Intensity: Management downplayed concerns about increased clinical reviews, asserting that their experience and existing teams effectively manage these challenges without significant impact on business.
• Acquisition Strategy: The company is focusing on smaller, manageable acquisitions and has successfully adapted its approach to larger portfolio deals by breaking them into smaller clusters.
• Labor Management: Improvements in labor metrics were attributed to enhanced data visibility and best practice sharing among local leaders.
• Behavioral Health Opportunities: Management acknowledged ongoing demand for specialized behavioral health services but emphasized a cautious, localized approach to expansion in this area.

Overall, Ensign Group reported strong financial performance in Q1 2026, driven by high occupancy rates and effective management strategies, while also navigating potential challenges related to managed care scrutiny and seasonal fluctuations.